US-based Arena Pharmaceuticals formed a development and commercialisation alliance with Chinese C-Bridge Capital-backed Everest Medicines for offering ralinepag and etrasimod in selected Asian countries.

Arena’s etrasimod is an oral, Phase II selective modulator of sphingosine 1-phosphate (S1P) receptors, and ralinepag is a Phase III-ready selective prostacyclin receptor agonist.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Etrasimod has the potential for use in autoimmune disorders, while ralinepag is being developed for pulmonary arterial hypertension (PAH).

Under the agreement, Everest holds the exclusive rights to develop and commercialise the drug candidates in mainland China, Taiwan, Hong Kong, Macau and South Korea.

Arena is set to obtain an upfront payment of $12m, followed by up to $212m at various development and commercial milestones.

“With new regulations in place in China to expedite approvals, a significant opportunity for ralinepag and etrasimod exists in early synchronisation of development programmes.”

While the firms intend to jointly develop the investigational drugs, Everest will fund the process of development and commercialisation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Arena Pharmaceuticals president and CEO Amit Munshi said: “With new regulations in place in China to expedite approvals, a significant opportunity for ralinepag and etrasimod exists in early synchronisation of development programmes.

“Based on their development and commercialisation expertise, as well as strategy for leveraging changes in the regulatory environment, we view Everest as the ideal partner to maximise the value of our drugs in the rapidly growing Chinese market.”

C-Bridge has invested $50m in Everest and formed a team to accelerate the product candidates towards approval and launch.

C-Bridge Capital CEO Fu Wei said: “Our strong belief in Everest’s capability to be the partner-of-choice for companies with innovative assets with large commercial potential in China is illustrated by our significant investment in Everest’s Series A round.”